Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Inclusion Criteria: * Histologically confirmed aggressive non-Hodgkin's lymphoma * Diffuse mixed cell * Diffuse large cell * Immunoblastic Follicular large cell with more than 50% large cells * Mantle cell * Non-age adjusted International Prognostic Index 2-4 * Tumor sample safely accessible by biopsy, needle aspiration, or phlebotomy * Must have adequate circulating lymphoma cells * Over 18 years old * Karnofsky 80-100% * WBC greater than 2,500/mm3 * Platelet count greater than 100,000/mm3 * Hemoglobin at least 10 g/dL * Bilirubin less than 2.0 mg/dL SGOT/SGPT less than 2 times normal * Creatinine less than 2.0 mg/dL * Fertile patients must use effective contraception during and for 6 months after the study * At least 2 months since prior nonphysiologic doses of prednisone of greater than 20 mg or equivalent * HIV negative Exclusion Criteria: * No CNS metastasis * No other illness or condition, including innate or pharmacologic immunosuppression, that would preclude study * No other malignancy within the last 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix * Not pregnant or nursing/negative pregnancy test * No prior biologic therapy for lymphoma * No prior cytotoxic chemotherapy for lymphoma * No prior steroids for lymphoma * No concurrent maintenance steroids or greater than 5mg of daily prednisone or equivalent * No prior radiotherapy for lymphoma